Cardiac fibrosis and high levels of circulating collagen markers has been associated with left ventricular (LV) hypertrophy. However, the relationship to vascular hypertrophy and blood pressure (BP) load is unclear. In 204 patients with essential hypertension and electrocardiographic LV hypertrophy, we measured sitting BP, serum collagen type I carboxy-terminal telopeptide (ICTP) reflecting degradation, procollagen type I carboxy-terminal propeptide (PICP) reflecting synthesis and LV mass by echocardiography after 2 weeks of placebo treatment and after 1 year of antihypertensive treatment with a losartan-or an atenolol-based regimen. Furthermore, we measured intima-media thickness of the common carotid arteries (IMT), minimal forearm vascular resistance (MFVR) by plethysmography and ambulatory 24-h BP in around half of the patients. At baseline, PICP/ICTP was positively related to IMT (r ¼ 0.24, Po0.05), MFVR men (r ¼ 0.35, Po0.01), 24-h systolic BP (r ¼ 0.24, Po0.05) and 24-h diastolic BP (r ¼ 0.22, Po0.05), but not to LV mass. After 1 year of treatment with reduction in systolic BP (175715 vs 151717 mmHg, Po0.001) and diastolic BP (9978 vs 8879 mmHg, Po0.001), ICTP was unchanged (3.771.4 vs 3.871.4 lg/l, NS) while PICP (121739 vs 102729 lg/l, Po0.001) decreased. The reduction in PICP/ICTP was related to the reduction in sitting diastolic BP (r ¼ 0.31, Po0.01) and regression of IMT (r ¼ 0.37, Po0.05) in patients receiving atenolol and to reduction in heart rate in patients receiving losartan (r ¼ 0.30, Po0.01). In conclusion, collagen markers reflecting net synthesis of type I collagen were positively related to vascular hypertrophy and BP load, suggesting that collagen synthesis in the vascular wall is increased in relation to high haemodynamic load in a reversible manner.
Introduction
Left ventricular (LV) hypertrophy is a strong cardiovascular risk factor in hypertension 1 although it is benign in athletes. 2 This difference has partly been explained by the fact that hypertensive LV hypertrophy is associated with vascular rarefaction and interstitial and perivascular fibrosis. 3 This myocardial fibrosis has, together with LV hypertrophy and diastolic dysfunction, been related to circulating collagen markers reflecting synthesis or degradation of type I and III collagen. 4 Type I collagen is more stable with a slower turnover whereas type III collagen is more dynamic with a higher turnover which is reflected by more type I collagen in bone tissue and more type III collagen in the cardiovascular system. Myocardial fibrosis in transgenic (mRen2)27 rats was prevented by normalization of blood pressure (BP) 5 and postmyocardial infarction changes in type I collagen in the right ventricle were closely related to changes in diastolic BP, 6 indicating a causal relationship between haemodynamic stress, fibrosis and collagen markers. However, in other animal studies 7 and in essential hypertension the regression of myocardial fibrosis has been related to blockade of the renin-angiotensin-aldosterone system in addition to reduction in BP. 8 Patients with hypertension often have hypertrophy and reduced compliance in the conduit arteries, which may be related to an increased amount of collagen in the vessel wall, 9 thereby predisposing to increased levels of circulating collagen markers in the blood. Furthermore, antihypertensive treatment known to increase compliance and reduce vascular hypertrophy 10 may also reduce vascular fibrosis. 11 The 'Losartan Intervention For EndpointReduction in Hypertension' (LIFE) trial, 12 which was an intervention study testing the effect of losartan-vs atenolol-based antihypertensive treatment on cardiovascular events, included patients with hypertension and electrocardiopgraphic LV hypertrophy having higher risk of myocardial fibrosis. 13 The present study was undertaken to investigate the relations between circulating collagen markers and LV mass, central vascular stiffness, total peripheral resistance, central and peripheral vascular hypertrophy and BP load in hypertension. Furthermore, we investigated whether circulating collagen markers were reduced after 1 year of antihypertensive treatment and whether the reduction was related to reduction of LV mass or of BP per se.
Methods

Subjects
We studied 204 patients (70 women) with essential hypertension and LV hypertrophy as determined by screening electrocardiogram after about 2 weeks of placebo treatment. All patients were participants in the LIFE trial, 12 and met the studys inclusion and exclusion criteria. We excluded patients receiving anti-inflammatory steroids, with major operation during the last 6 months, severe osteoporosis, healing wounds, known malignant, hepatic or thyroid disease based on history as well as liver enzymes and thyroid hormones. Patients applying to the inclusion and exclusion criteria were included consecutively at Ullevall University Hospital in Norway or Naestved Country Hospital, Frederiksberg University Hospital or Glostrup University Hospital in Denmark. There were no significant patient differences between the centres. The mean duration of known hypertension ranged from 0 to 35 years. A total of 42 patients had newly diagnosed hypertension. Prior to the washout placebo-period, 79 patients had received b-receptor antagonists or diuretics. In total, 110 patients had received vasodilators such as calcium antagonists, angiotensinconverting-enzyme inhibitors, angiotensin II-receptor blockers or carvedilol. Framingham Risk Score was calculated.
14 Further patient characteristics are listed in Table 1 .
Protocol and methods
BP in sitting position
According to the main protocol, resting sitting BP was measured after about 2 weeks of placebo treatment and after 1 year of active antihypertensive treatment with a losartan-or an atenolol-based regimen using a manual mercury sphygmomanometer.
Echocardiography
At baseline and after 1 year of antihypertensive treatment, an echocardiogram was performed in 186 patients following a previously employed protocol. 15 Standardized examinations included two dimensional (2-D) guided M-mode echocardiograms and selected 2-D recordings. Measurements were made blindly at the Echocardiography Reading Center at The New York Presbyterian Hospital-Weill Medical College of Cornell University in New York City by experienced physician readers using computerized review stations (Digisonics, Inc., Houston, TX, USA). LV dimensions were measured according to recommendations of the American Society of Echocardiography. When optimal orientation of the LV or atrial imaging views could not be obtained, correctly oriented 2-D linear dimension measurements were made by the leading-edge convention. LV end-diastolic diameter and wall thickness were used to calculate relative wall thickness and LV mass. 15 Stroke volume was calculated by the invasively validated aortic annular-leading edge method as (aortic annular cross-sectional area) Â (Doppler time velocity integral of aortic annular flow) 16 and used to calculate cardiac output and total peripheral resistance. The pulse pressure/stroke volume ratio 
Ambulatory BP
An automatic BP device that measured ambulatory BP using the cuff-oscillometric method (Takeda TM-2421, A&D Co. Ltd, Tokyo, Japan) 18 was applied to the left arm and worn for 24 h in 98 patients at baseline. Oscillometric BP were measured every half hour during daytime and every hour at night (2300 to 0600 hours). There were more than 20 readable measurements during 24 h in all patients, considered to be sufficient 19 to calculate median 24-h BP. Owing to relative few measurements in some of the patients we have used median values which are more resistant to influence of outliers.
Carotid ultrasound
At baseline and after 1 year of treatment intimamedia thickness (IMT) and the lumen diameter of the common carotid arteries were measured in 95 patients by ultrasound using the ACUSON 128XP/10c (Acuson Corporation, CA, USA) and a linear 7 MHz transducer. IMT of the right and left common carotid artery was measured in the 1-cm segment proximal to the dilation of the carotid bulb as described by Howard et al. 20 The longitudinal B-mode image was accepted as valid when a double line resembling lumen-intima and media-adventitia interfaces was visualized in the longest possible segment on near as well as far wall. The images were digitized and IMT of the far walls of the left as well as of the right common carotid artery were measured by a technician without any knowledge of patient characteristics using a PC Iô Workstation (Iô DP, Medical Imaging Solutions, Paris, France). IMT was calculated as a mean thickness over a 1-cm segment reducing the impact of atherosclerotic plaques making IMT more a measure of vascular hypertrophy than atherosclerosis.
Forearm blood flow
At baseline, the maximal forearm blood flow was measured in 89 patients after 10 min of ischaemia using strain gauge plethysmography (Model EC5R, Hokanson, Inc., Bellevue, WA, USA). 21 A wristoccluding cuff was used. Forearm blood flow was measured 6-10 times during the first minute of hyperaemia and was expressed as ml per 100 ml tissue per minute. At the same time, BP was measured three times with a semiautomatic sphygmanometer (Dinamap-Model 1846 SX, Critikon, Johnson & Johnson, Medical Inc., USA). Among the 6-10 forearm blood flow measurements during the first minute of hyperaemia the highest value was chosen to represent the maximal forearm blood flow. Minimal forearm vascular resistance (MFVR) was calculated as the corresponding mean BP divided by the maximal forearm blood flow. We chose to analyse MFVR in men and women separately as MFVR-values and standard variations were much higher in the more obese women (3.171.42 vs 2.370.48 mmHg min 100), probably due to lower percentage muscle tissue in their forearms. 22 
Assays
After about 2 weeks of placebo treatment and after 1 year of active antihypertensive treatment with a losartan-or an atenolol-based regimen the following collagen markers were measured 23 in serum: Procollagen type I carboxyterminal propeptide (PICP) reflecting synthesis of type I collagen, collagen type I carboxyterminal telopeptide (ICTP) reflecting degradation of type I collagen, procollagen type I aminoterminal propeptide (PINP) reflecting turnover (the sum of synthesis and degradation) of type I collagen and procollagen type III aminoterminal propeptide (PIIINP) reflecting turnover (synthesis as well as degradation) of type III collagen. 23 PICP/ ICTP is thought to reflect net synthesis of type I collagen. 24 Serum concentrations of PICP, PINP, ICTP and PIIINP were measured with radioimmunoassays purchased from Orion, Finland. All samples were measured according to instructions from the manufacturer and in duplicate. Inter-and intraassay coefficients of variation (range 4-7%), and unspecific binding (range 2-9%) were low.
Statistics
For data management and statistical analyses, Statistica 5.1 (StatSoft, Inc., Tulsa, OK, USA) was used. Parametric statistics were used calculating mean values and 95%-confidence intervals. Gender differences as well as differences between the two pressure groups were analysed using unpaired t-test. Changes over time within patients were analysed using paired t-test. We performed simple linear regression analyses calculating Pearson's correlation coefficient (r) and stepwise, backward multiple linear regression analyses calculating the standardized regression coefficient for each parameter (b) and the common adjusted coefficient of determination for the model (adj. R 2 ). Baseline and 1-year data were not included in the same model. Nonsignificant parameters were excluded from the model. Two-tailed P-values o0.05 were considered statistically significant.
Results
At
Increased synthesis of type I collagen, assessed as high PICP, was associated with higher age, higher 24-h ambulatory BP and more vascular hypertrophy with higher peripheral resistance and lower vascular compliance. Increased degradation of type I collagen, assessed as high ICTP, was associated with higher age, higher Framingham Risk Score and lower kidney function. To correct for differences in renal elimination of ICTP, we divided ICTP with serum creatinine. High ICTP/creatinine was associated with low IMT (r ¼ À0.21, P ¼ 0.06), low MFVR in men (r ¼ À0.25, P ¼ 0.05) and low mitral valve deceleration time (r ¼ À0.15, Po0.05). High PICP/ ICTP was associated with higher 24-h ambulatory BP, IMT, MFVR, total peripheral resistance and serum cholesterol together with lower body mass index (Table 2) . High PIIINP, which is thought to reflect turnover of type III collagen, was associated with higher LV mass, larger lumen of the common carotid arteries, higher mitral early/late peak flow velocity ratio (r ¼ 0.16, Po0.05) and higher body surface area (Table 2) . Collagen markers were not significantly related to any of the other echocardiographic parameters ( Table 2) . None of the collagen markers were related to serum alanine aminotransferase.
In multiple regression analyses, high PICP/ICTP (adj. After 1 year of treatment with marked reduction in BP, regression of LV hypertrophy and improved LV diastolic filling (Table 3) , PIIINP was unchanged, ICTP increased insignificantly, PICP and PINP decreased (Table 4 ). Looking at the whole population, increase in ICTP and reduction in PICP/ICTP were associated with reduction in sitting diastolic BP and reduction in heart rate ( Table 5) . The correlations to changes in heart rate were only present in patients receiving losartan and the correlations between changes in BP and PICP, PINP as well as PICP/ICTP were only present in patents receiving atenolol (Table 5 ). However, reduction in diastolic BP was only associated with increased ICTP and ICTP/creatinine (r ¼ À0.22, Po0.05) in patients receiving losartan. Reduction in heart rate was also associated with increased ICTP/creatinine (r ¼ À0.25, Po0.05) in patients receiving losartan. We did not find any significant relationships between changes in 24-h ambulatory BP and changes in circulating collagen markers probably because of few ambulatory BP measurements at 1 year.
In the whole population, reductions in carotid artery lumen (r ¼ À0.23, Po0.05) and to some degree IMA (r ¼ À0.20, P ¼ 0.09) were weakly associated with increase in PICP/ICTP. These associations were largely driven by patients receiving losartan in whom reductions in carotid artery lumen and IMA were associated with increases in PICP (r ¼ À0.35 and À0.36, both Po0.05) as well as PICP/ICTP (r ¼ À0.34, Po0.05 and r ¼ À0.42, Po0.01). Actually in patients receiving atenolol, reductions in IMT (r ¼ 0.37, Po0.05) and IMA (r ¼ 0.32, Po0.05) were associated with decreases in PICP. In the whole population, reductions in IMT (r ¼ 0.23, Po0.05) and IMA (r ¼ 0.25, Po0.05) were associated with reductions in ICTP/creatinine independently of treatment. Changes in LV mass, relative wall thickness, plasma glucose or serum cholesterol during 1 year of treatment were not associated with changes in any of the collagen markers. Reductions in LV IVRT (r ¼ À0.16, P ¼ 0.07) and deceleration time (r ¼ À0.18, Po0.05) were weakly associated with increases in PIIINP independently of treatment group. The results did not change substantially when using relative values.
Discussion
At baseline higher PICP/ICTP, reflecting net elevated synthesis of type I collagen, was associated with high BP load assessed by 24-h ambulatory BP. The reduction in PICP/ICTP was associated with the BP reduction in patients receiving atenolol-based antihypertensive treatment, whereas it was associated with the reduction in heart rate in patients receiving losartan-based antihypertensive treatment, even though the reduction in heart rate was more pronounced in patients receiving atenolol-based antihypertensive treatment. The reduction in circulating collagen markers during the first year of treatment was equal in the two groups. This suggests that cardiovascular fibrosis, assessed by circulating collagen markers, is related to haemodynamic load as previously shown in animals, 5, 6 which, to some degree, is in contrast to the limited human data 8 stating that BP reduction without blocking the renin-angiotensin-aldosterone system is unable to reduce cardiac fibrosis and circulating collagen markers. However, the fact that the reduction in PICP/ICTP seen in patients receiving losartan was not associated with the reduction in BP may indicate a BP-independent mechanism of action for losartan on collagen synthesis 3 supporting the hypothesis of a superior effect of blockers of the renin-angiotensin-aldosterone system in reducing fibrosis. The lack of relationship to BP in the losartan group may also reflect that brachial artery BP does not reflect aortic BP very well in patients treated with an angiotensin II receptor blocker. The lack of relationship between BP and circulating collagen markers in previous studies 8 may also be due to use of office BP in small groups of patients increasing the risk of type 2 error. The hypothesis that collagen synthesis assessed by collagen markers is related to haemodynamic load is supported by data from another LIFE substudy 25 demonstrating that circulating collagen markers began to change within the first month of antihypertensive treatment before any changes in cardiovascular hypertrophy may be likely to occur. As circulating collagen markers was reduced equally in the two groups, these data did not offer an explanation for the lower incidence of cardiovascular events in patients treated with losartan vs atenolol in the LIFE study. However, the fact that the reduction in collagen synthesis was independent of the BP reduction in patients treated with losartan opens for the possibility of further reduction in collagen synthesis beyond the first year of treatment with losartanbased antihypertensive treatment despite only small changes in BP giving a possible explanation for the results of the LIFE study.
At baseline, high PICP/ICTP was associated with vascular hypertrophy assessed by IMT and MFVR men , but not to LV hypertrophy as previously demonstrated. 13 However, PIIINP was weakly related to LV hypertrophy. A possible explanation for the lack of association between PICP/ICTP and LV hypertrophy might be that most of the patients prior to this study had received antihypertensive treatment reducing BP, LV mass and probably also the level of circulating collagen markers. As BP rose during the 2 weeks of placebo treatment, we hypothesize that the level of circulating collagen markers increased before any changes in LV mass occurred dissociating collagen markers from LV mass. The lack of association between PICP/ICTP and LV hypertrophy may also just reflect a poor correlation between LV hypertrophy and LV fibrosis. 8 In patients receiving atenolol, regression of carotid hypertrophy was associated with reduction in PICP as expected. However, this relationship was to our surprise inverted in patients receiving losartan, which we cannot explain. Regression of carotid hypertrophy was independently of treatment associated with higher PIIINP, reflecting increased turnover of type III collagen, which might indicate a parallel reduction in vascular hypertrophy and fibrosis during antihypertensive treatment. At steady state at baseline high PIIINP, reflecting more type III collagen in the heart, 23 was associated with impaired LV diastolic filling as demonstrated by Diez et al. 13 During treatment increasing PIIINP, reflecting increased turnover of type III collagen, was associated with improved LV diastolic filling indicating a parallel reduction in LV hypertrophy and fibrosis. As seen before, PICP was lower in patients with high body mass index.
Although collagen synthesis assessed by the level of circulating collagen markers were related to BP load, BP only accounted for some of the variation in collagen synthesis. Cardiovascular fibrosis is important to be able to estimate, because it is associated with haemodynamic dysfunctions 26, 27 and possibly high cardiovascular mortality. 26 However, hypertrophy and fibrosis does not necessarily develop parallel. Therefore, it is likely that circulating collagen markers may prove to be independent predictors of cardiovascular risk. Furthermore, they may be useful in monitoring treatment in the individual patient as circulating collagen markers changes dynamically within few months and these changes may turn out to be able to predict later changes in cardiovascular fibrosis. 25 However, these hypotheses remain to be proven.
Limitations
The correlations are weak and do not establish any cause-effect relationship. The patient group was heterogeneous in regard to duration and type of previous antihypertensive treatment which may have distorted some baseline relationships. However, this also suggests that the strength of the demonstrated relationships may have been underestimated.
Conclusions
Collagen markers reflecting net synthesis of type I collagen were positively related to vascular hypertrophy and BP load at baseline and during treatment with atenolol-based antihypertensive treatment suggesting that collagen synthesis in the vascular wall is increased in relation to high BP load and may be reduced by BP reduction possibly predicting later regression in cardiovascular fibrosis/hypertrophy. In patients treated with a losartan-based regimen, PICP/ICTP was reduced independently of BP indicating a BP-independent mechanism of action. Collagen type III turnover was increased in patients with LV hypertrophy and impaired LV diastolic filling and increased PIIINP during treatment was associated with improved diastolic filling.
